All In Biotech

Drug Trial Radar · NCT05753930

Imlifidase Prior to Kidney Transplant in Highly Sensitised Children

A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converted to Negative After Imlifidase Treatment

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Jun 2, 2023

Primary completion

Feb 28, 2027

Study completion Aug 31, 2031

Sponsor

Lead sponsor
Hansa Biopharma ABIndustry
Sponsor type
Industry
First posted
Mar 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the efficacy and safety of imlifidase in highly sensitized paediatric patients, 1-17 years old, with end stage renal disease (ESRD). The main questions it aims to answer are: * Does imlifidase treatment result in crossmatch conversion that enables transplantation? * How is the function of the transplanted kidney? The participants will be hospitalised in accordance with the normal routines for transplanted patients. The patients will receive medication to prevent rejection of the donor kidney, and because such treatment make the body more vulnerable medications to prevent infections.

Conditions

  • Kidney Transplantation in Highly Sensitized Patients

Interventions

  • ImlifidaseDrug

    Imlifidase is an immunoglobulin G (IgG)-degrading enzyme of Streptococcus pyogenes that is highly selective towards IgG. The cleavage of IgG generates one F(ab')2- and one homodimeric Fc-fragment and efficiently neutralizes Fc-mediated activities of IgG.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with conversion of a positive crossmatch test to negative within 24 hours after start of imlifidase treatmentTime frame: From start of imlifidase administration to 24 hours

Locations

7 sites in 6 countries. Site status is shown where the registry gives one.

  • HUS, Helsinki University Hospital

    Helsinki, Finland · Withdrawn

  • Robert Debre University Hospital

    Paris, France · Recruiting

  • Ospedale Pediatrico Bambino Gesu

    Rome, Italy · Not yet recruiting

  • Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica

    Barcelona, Spain · Recruiting

  • Hospital Sant Joan De Deu Barcelona

    Barcelona, Spain · Not yet recruiting

  • Karolinska University Hospital

    Huddinge, Stockholm County, Sweden · Recruiting

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.